This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Safety

Somavert has an established safety and tolerability profile1-2

Somavert safety profile

Over 2000 patients have participated in ACROSTUDY, the global safety surveillance study for Somavert to date, providing a wealth of information about possible adverse events1,2

Card CTA

** This is an optional area where footnotes can live.

Monitoring of liver tests

Liver function should be monitored at baseline and every 4-6 weeks on treatment, and more frequently if elevations are detected​​​​​​​1

Why target IGF-1?

Professor AJ van der Lely, Erasmus MC, Rotterdam, Netherlands, explains the vital role of IGF-I, the liver and insulin production in acromegaly and its treatment

Discover more webinars

Track IGF-I, symptoms and co-morbidities with ACRODAT

Learn more

Explore more

Contact us

To find out more about ACRODAT, supporting your patients or to order starter kits

Contact us

** This is an optional area where footnotes can live.

Starter kits

Help your patients feel confident with Somavert and self-administration 

Learn more

** This is an optional area where footnotes can live.
References​​​​​
  1. Somavert Summary of Product Characteristics. Available here​​​​​​​
  2. Buchfelder M, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol, 2018;179(6):419–27.
PP-SOM-GBR-0952. June 2021

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No